Pfizer Corp. has just made its first contribution to ophthalmology at the University of Ottawa Eye Institute. The corporation donated $75,000 towards vision research, the first of three instalments totalling $225,000.
This contribution will help ensure the creation of a new floor devoted to age-related blindness, also known as age-related macular degeneration (AMD). AMD is a disease that blurs the sharp, central vision needed for ‘straight-ahead’ activities such as reading, sewing and driving.
The new floor – to be added to Tower 3 on top of the Eye Institute floor at the General Campus – will provide the best in technology and resources to help understand age related blindness in the hope of slowing or preventing its progression.
